The opioid antagonist naloxone inhibits Leishmania major infection in BALB/c mice

Experimental Parasitology

Volumn 130, Issue 1, 2012, Pages 73-77

  Karaji, Ali Gorgin ^a   Hamzavi, Yazdan ^a  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

IFN ; IL 4; Immune modulation; Leishmania major; Naloxone

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; NALOXONE; OPIATE ANTAGONIST; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING KINETICS; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; GROWTH INHIBITION; IMMUNOMODULATION; INFECTION PREVENTION; INFECTION SENSITIVITY; LEISHMANIASIS; LOW DRUG DOSE; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TREATMENT DURATION;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERFERON-GAMMA; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; NALOXONE; NARCOTIC ANTAGONISTS;

LEISHMANIA MAJOR; MUS;

EID: 84855968532     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.09.006     Document Type: Article

References (26)

1. Albrizio M., Guaricci A.C., Maritato F., Sciorsci R.L., Mari G., Calamita G., Lacalandra G.M., Aiudi G.G., Minoia R., Dell'Aquila M.E., Minoia P.M. Expression and subcellular localization of the mu-opioid receptor in equine spermatozoa: evidence for its functional role. Reproduction 2005, 129:39-49.
2. Belosevic M., Finbloom D.S., Van Der Meide P.H., Slayter M.V., Nacy C.A. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. Journal of Immunology 1989, 143:266-274.
3. Charlton B., Lafferty K.J. The Th1/Th2 balance in autoimmunity. Current Opinion in Immunology 1995, 7:793-798.
4. Cosola C., Albrizio M., Guaricci A.C., De Salvia M.A., Zarrilli A., Sciorsci R.L., Minoia R. Opioid agonist/antagonist effect of naloxone in modulating rabbit jejunum contractility in vitro. Journal of Physiology and Pharmacology 2006, 57:439-449.
5. Dell'Aquila M.E., Casavola V., Reshkin S.J., Albrizio M., Guerra L., Maritato F., Minoia P. Effects of beta-endorphin and naloxone on in vitro maturation of bovine oocytes. Molecular Reproduction and Development 2002, 63:210-222.
6. Desjeux P. Leishmaniasis. Public health aspects and control. Clinics in Dermatology 1996, 14:417-423.
7. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. Journal of Experimental Medicine 1989, 169:59-72.
8. Heinzel F.P., Sadick M.D., Mutha S.S., Locksley R.M. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. National Academy of Sciences of the United States of America 1991, 88:7011-7015.
9. Howard J.G., Hale C., Chan-Liew W.L. Immunological regulation of experimental cutaneous leishmaniasis. 1. Immunogenetic aspects of susceptibility to Leishmania tropica in mice. Parasite Immunology 1980, 2:303-314.
10. Hutchinson M.R., Zhang Y., Shridhar M., Evans J.H., Buchanan M.M., Zhao T.X., Slivka P.F., Coats B.D., Rezvani N., Wieseler J., Hughes T.S., Landgraf K.E., Chan S., Fong S., Phipps S., Falke J.J., Leinwand L.A., Maier S.F., Yin H., Rice K.C., Watkins L.R. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain, Behavior, and Immunity 2010, 24:83-95.
11. Khamesipour A., Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., Modabber F. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 23:3642-3648.
12. Lohoff M., Ferrick D., Mittrucker H.W., Duncan G.S., Bischof S., Rollinghoff M., Mak T.W. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 1997, 6:681-689.
13. Manfredi B., Sacerdote P., Bianchi M., Locatelli L., Veljic-Radulovic J., Panerai A.E. Evidence for an opioid inhibitory effect on T cell proliferation. Journal of Neuroimmunology 1993, 44:43-48.
14. Nickerson P., Steurer W., Steiger J., Zheng X., Steele A.W., Strom T.B. Cytokines and the Th1/Th2 paradigm in transplantation. Current Opinion in Immunology 1994, 6:757-764.
15. Panerai A.E., Manfredi B., Granucci F., Sacerdote P. The beta-endorphin inhibition of mitogen-induced splenocytes proliferation is mediated by central and peripheral paracrine/autocrine effects of the opioid. Journal of Neuroimmunology 1995, 58:71-76.
16. Panerai A.E., Radulovic J., Monastra G., Manfredi B., Locatelli L., Sacerdote P. Beta-endorphin concentrations in brain areas and peritoneal macrophages in rats susceptible and resistant to experimental allergic encephalomyelitis: a possible relationship between tumor necrosis factor alpha and opioids in the disease. Journal of Neuroimmunology 1994, 51:169-176.
17. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Annual Review of Immunology 1995, 13:151-177.
18. Sacerdote P., Manfredi B., Bianchi M., Panerai A.E. Intermittent but not continuous inescapable foot shock stress affects immune responses and immunocyte beta-endorphin concentrations in the rat. Brain, Behavior, and Immunity 1994, 8:251-260.
19. Sacerdote P., Bianchi M., Panerai A.E. Involvement of beta-endorphin in the modulation of paw inflammatory edema in the rat. Regulatory Peptides 1996, 63:79-83.
20. Sacerdote P., di San Secondo V.E., Sirchia G., Manfredi B., Panerai A.E. Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines. Clinical and Experimental Immunology 1998, 113:465-469.
21. Sacerdote P., Manfredi B., Gaspani L., Panerai A.E. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 2000, 95:2031-2036.
22. Singh S., Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. Journal of Infection and Chemotherapy 2004, 10:307-315.
23. Tominaga N., Ohkusu-Tsukada K., Udono H., Abe R., Matsuyama T., Yui K. Development of Th1 and not Th2 immune responses in mice lacking IFN-regulatory factor-4. International Immunology 2003, 15:1-10.
24. Wang Z.E., Reiner S.L., Zheng S., Dalton D.K., Locksley R.M. CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. Journal of Experimental Medicine 1994, 179:1367-1371.
25. Wang Z.E., Zheng S., Corry D.B., Dalton D.K., Seder R.A., Reiner S.L., Locksley R.M. Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:12932-12936.
26. Wu H.E., Sun H.S., Cheng C.W., Terashvili M., Tseng L.F. Dextro-naloxone or levo-naloxone reverses the attenuation of morphine antinociception induced by lipopolysaccharide in the mouse spinal cord via a non-opioid mechanism. European Journal of Neuroscience 2006, 24:2575-2580.